Luo L, Sabara M I
National Centre for Foreign Animal Disease, Canadian Science Centre for Human and Animal Health, Winnipeg, Manitoba R3E 3M4, Canada.
Transbound Emerg Dis. 2008 May;55(3-4):175-82. doi: 10.1111/j.1865-1682.2008.01022.x.
The predominant serodiagnostic assay used in many countries to detect bluetongue virus (BTV) infections is a competitive enzyme-linked immunosorbent assay (c-ELISA) which employs two critical reagents: a cell culture-derived BTV antigen and group-specific monoclonal antibody (Mab). Ongoing difficulties have been reported by laboratories in the production and quality control of the native antigen reagent which relies on the presence of adequate molar quantities and appropriate presentation of the major BTV core protein VP7. To address this important issue, a recombinant baculovirus was constructed containing a cDNA copy of genome segment 7 of BTV serotype 11 and used to infect insect cells which, in turn, expressed high levels of theVP7 protein with an estimated molecular mass of 39 kDa. In its purified form, this recombinant protein could be detected by group-specific Mabs designated 3.17.A3 and 8A3B.6 produced against BTV serotypes 1 and 17, respectively, as well as by polyclonal bovine antibodies raised against North American and South African BTV serotypes. No reactivity was observed by Western blot analysis with these two Mabs suggesting that the common antigenic determinants, on the BTV VP7 protein, were mainly conformational. It was interesting to note that the purified recombinant VP7 protein demonstrated a greater degree of reactivity with Mab 8A3B.6 compared to that exhibited with Mab 3.17.A3 when evaluated in an ELISA. Due to its antigenic similarity to the native antigen, the recombinant protein was found to be a suitable replacement for use in a c-ELISA to detect BTV-specific antibodies with the added advantage that it could be consistently produced and was, therefore, amenable to quality control testing for purity, stability and other standards.
许多国家用于检测蓝舌病病毒(BTV)感染的主要血清学诊断方法是竞争酶联免疫吸附测定(c-ELISA),该方法使用两种关键试剂:细胞培养衍生的BTV抗原和组特异性单克隆抗体(Mab)。据实验室报告,在天然抗原试剂的生产和质量控制方面一直存在困难,这种试剂依赖于主要BTV核心蛋白VP7的足够摩尔量和适当呈现。为了解决这个重要问题,构建了一种重组杆状病毒,其包含BTV血清型11基因组片段7的cDNA拷贝,并用于感染昆虫细胞,昆虫细胞进而表达高水平的估计分子量为39 kDa的VP7蛋白。以纯化形式,这种重组蛋白可以被分别针对BTV血清型1和17产生的组特异性单克隆抗体3.17.A3和8A3B.6以及针对北美和南非BTV血清型产生的多克隆牛抗体检测到。用这两种单克隆抗体进行蛋白质印迹分析未观察到反应性,这表明BTV VP7蛋白上的共同抗原决定簇主要是构象性的。有趣的是,当在ELISA中评估时,纯化的重组VP7蛋白与单克隆抗体8A3B.6相比,与单克隆抗体3.17.A3表现出更高程度的反应性。由于其与天然抗原的抗原相似性,发现该重组蛋白是用于c-ELISA检测BTV特异性抗体的合适替代品,其额外优点是可以持续生产,因此适合进行纯度、稳定性和其他标准的质量控制测试。